



Xiaotong Song, PhD

Associate Professor

Center for Infectious and Inflammatory Diseases

Texas A&M Univ. Institute of Biosciences & Technology

Refueled CAR T Cell Therapy to Cure Solid Tumor

Dr. Xiaotong Song is an Associate Professor at the Institute of Biosciences & Technology (IBT), Department of Translational Medical Sciences, with the Texas A&M School of Medicine. He obtained his MD from Peking University Health Science Center in 1993 and completed his PhD in Immunology at Nanjing Medical University in 2002. Following this, Dr. Song pursued postdoctoral training at the Center for Cell and Gene Therapy (CAGT) at BCM in 2003. In 2010, Dr. Song was appointed as a Tenure-track Assistant Professor at CAGT, where he led a group focused on adoptive cell therapies, vaccines, and oncolytic viral therapies. His research at CAGT/BCM received funding through NIH R01 and DOD awards.

In 2016, Dr. Song founded Icell Kealex Therapeutics and served as the full-time CEO. Under his leadership, the company conducted IND enabling studies for oncolytic vaccinia virus targeting solid tumors, securing a multimillion-dollar investment from the Cancer Prevention and & Research Institute of Texas (CPRIT) and NIH SBIR, leading to a successful exit in 2020. Dr. Song is a serial entrepreneur, having co-founded several startups (4 VC-backed, >\$43M raised, 1 exited). Currently, Dr. Song is dedicated to developing a unique and disruptive CAR T cell platform for solid tumor by addressing the limitations of current CAR T cell therapies.